Emalex Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Emalex Biosciences sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Emalex Biosciences: 14 sponsored US clinical trials, none currently recruiting.

Emalex Biosciences sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Childhood-Onset Fluency Disorder (Stuttering), with 1 trials.

Top-decile sponsor footprint

Emalex Biosciences ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

14 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522
COMPLETED Phase 1

Food-effect Study of Ecopipam Pharmacokinetics

NCT06669091
COMPLETED Phase 1

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

NCT05841160
COMPLETED Phase 3

Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

NCT05615220
COMPLETED Phase 1

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
COMPLETED Phase 1

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04902105
TERMINATED Phase 1

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851
COMPLETED Phase 2

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

NCT04492956
COMPLETED Phase 2

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

NCT04114539
COMPLETED Phase 2

Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

NCT04007991
COMPLETED Phase 2

Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

NCT02102698
TERMINATED Phase 3

Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

NCT01751802
COMPLETED Phase 1

Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam

NCT01408394
COMPLETED Phase 2

Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

NCT01215357

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 5
Phase 3 3

Therapeutic Areas

Childhood-Onset Fluency Disorder (Stuttering) 1
Tourette Syndrome 1
Healthy 1

How the Emalex Biosciences early-phase archive is shaped

14 indexed studies, none listed as recruiting (0% open); 11 completed (79%).

Phase mix: 3 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Childhood-Onset Fluency Disorder (Stuttering) (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Emalex Biosciences: archived-pipeline peers nationwide

Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Emalex Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Emalex Biosciences3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA10xBio22nd Century Group23andMe3 Waves Wellness
Emalex Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emalex Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Emalex Biosciences page

14 registered trials is a research-attention snapshot, not an endorsement of Emalex Biosciences or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Emalex Biosciences pipeline card: 14 registered trials from official public datasets.Report a data error.